| Title |
Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience
|
|---|---|
| Published in |
International Journal of Hematology, September 2017
|
| DOI | 10.1007/s12185-017-2325-y |
| Pubmed ID | |
| Authors |
Ahmed S. Al Askar, Naila A. Shaheen, Mohsen Al Zahrani, Mohammed G. Al Otaibi, Bader S. Al Qahtani, Faris Ahmed, Mohand Al Zughaibi, Ismat Kamran, May Anne Mendoza, Altaf Khan |
| Abstract |
Immune thrombocytopenic purpura (ITP) is a common hematological disease treated primarily by corticosteroids. The aim of the present study was to compare response rate between patients, underwent splenectomy vs. rituximab as second-line therapy. Adult patients diagnosed with ITP who did not respond to corticosteroids or relapsed during the period 1990-2014 were included in a quasi-experimental study. Categorical variables were compared using Fisher exact test. Response to treatment was compared using logistic regression. Data were analyzed using SAS V9.2. One-hundred and forty-three patients with ITP were identified through medical records. Of 62 patients treated, 30 (48.38%) required second-line therapy. 19 (63%) patients received rituximab, and 11 (37%) underwent splenectomy. Platelets at diagnosis were not different between study groups (p = 0.062). Splenectomy group patients were younger (p = 0.011). Response to second-line therapy showed no significant difference between two groups (OR 2.03, 95% CI (0.21-22.09), p = 0.549). Results did not show a statistically significant difference in platelet counts over time between treatment groups (p = 0.101). When used exclusively as a second-line therapy for steroid-refractory ITP, the response rate was not statistically different between rituximab and splenectomy. However, further large studies are needed to assess the response rates for these treatment modalities as a second-line therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 20% |
| Student > Doctoral Student | 2 | 13% |
| Student > Master | 2 | 13% |
| Student > Ph. D. Student | 1 | 7% |
| Student > Bachelor | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 5 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 47% |
| Nursing and Health Professions | 2 | 13% |
| Unknown | 6 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2017.
All research outputs
#4,339,170
of 23,509,253 outputs
Outputs from International Journal of Hematology
#99
of 1,436 outputs
Outputs of similar age
#75,317
of 317,015 outputs
Outputs of similar age from International Journal of Hematology
#3
of 18 outputs
Altmetric has tracked 23,509,253 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,436 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,015 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.